HER2 Diagnostics in Gastric Cancer
暂无分享,去创建一个
Dirk Zielinski | Thomas Henkel | T. Henkel | J. Rüschoff | O. Stoss | O. Stoss | Martina Schmitt | Iris Nagelmeier | J. Rüschoff | I. Nagelmeier | M. Schmitt | D. Zielinski
[1] M. Neyt,et al. An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] J. Metges,et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer , 2005, British Journal of Cancer.
[3] J. Elder,et al. Transforming growth factor alpha and epidermal growth factor levels in normal human gastrointestinal mucosa. , 1989, British Journal of Cancer.
[4] A. Iwamatsu,et al. Activation of ErbB3–PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas , 2003, Oncogene.
[5] T. Okuda,et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c‐erbb‐2 in human gastric cancer , 1995, Cancer.
[6] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[7] Janusz Jankowski,et al. Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas , 2006, Clinical Cancer Research.
[8] K. Kobayashi,et al. Immunohistologic detection of the epidermal growth factor receptor in human esophageal squamous cell carcinoma , 1991, Cancer.
[9] T. Hirao,et al. The prognostic significance of amplification and overexpression of c‐met and c‐erb B‐2 in human gastric carcinomas , 1999, Cancer.
[10] Y. Yarden,et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.
[11] H. Wiley,et al. Multiple Mechanisms Are Responsible for Transactivation of the Epidermal Growth Factor Receptor in Mammary Epithelial Cells* , 2008, Journal of Biological Chemistry.
[12] J. Isola,et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] E. Van Cutsem,et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] E. Cho,et al. HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer , 2006, Digestive Diseases and Sciences.
[15] N. Lemoine,et al. Expression of the c‐erbB‐3 gene product in gastric cancer , 1993, International journal of cancer.
[16] Peter A Kaufman,et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. , 2002, Journal of the National Cancer Institute.
[17] H. Nagawa,et al. Lysophospholipids transactivate HER2/neu (erbB-2) in human gastric cancer cells. , 2005, Biochemical and biophysical research communications.
[18] F. Schmitt,et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients , 2009, British Journal of Cancer.
[19] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[20] M. J. van de Vijver,et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study , 2008, Histopathology.